Skip to main content
Equibles
DSGN logo

DSGN · Design Therapeutics, Inc.

Track DSGN — free

Use DSGN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research DSGN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$14.63 -0.17 (-1.15%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$915.57M
Shares
62.58M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$14.63 Open$14.99 Day$14.43–15.14 52W close$5.53–15.94 Avg vol 30d551K Short int5.5M · 8.9% float · 9.0d Short vol79% Last earningsApr 28, 2026 DataMar 2021–Sep 2026 Filing10-Q · Aug 3

Up next

Next earnings call
Feb 20, 2027 Est · unconfirmed · in 23 wks
Latest filing: 10-Q
filed Aug 3, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$70.80M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-6.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$207.40M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+9.9%
Year over year · more shares
Price change (1Y)
+145.5%
Trailing year
Short interest
8.9%
Latest settlement · 9.0 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.60
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +24%
above
Price vs 50-day avg +4%
above
RSI (14) 48
neutral
MACD trend Negative
52-week position 87%
near high
Momentum
relative strength
Very Strong
1-month return +2%
trailing
6-month return +42%
trailing
YTD return +56%
this year
Relative strength +24%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $14 › 200d $12 — 50d above 200d
Institutional flow Accumulating
+9% holders QoQ · +28 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
8.86% of float · ▼ -6.5% MoM · 9.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
136 holders — near 3-yr high, broad support
Squeeze score 66
elevated · 0–100
Fundamentals
Poor
EPS growth −39%
Y/Y
Free cash flow $-54.6M
Quant / Vol
risk profile
Very High
Volatility 76%
annualized · 1-yr
Max drawdown −36%
past year
ATR 4.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
1 · 2 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+24% Bullish
Price vs 50-day avg
+4% Bullish
RSI (14)
48 Neutral
MACD trend
Negative Bearish
52-week position
87% Bullish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $14 › 200d $12 — 50d above 200d
Institutional flow Accumulating
+9% holders QoQ · +28 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
8.86% of float · ▼ -6.5% MoM · 9.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
136 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $6 Now $15 · 87% Range high $16
vs 200-day avg +24% vs 50-day avg +4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
DSGN
Design Therapeutics, Inc.
this stock
$915.57M +56.0% — — 8.9%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.40B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.67B +1.2% +20.8% 19.6 2.5%
ARGX
Argenx SE
 $61.60B +17.1% — — 2.0%
CSLLY
Csl Ltd
 $57.41B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
136
% held
71.7%
Net QoQ
+6.9M sh
Top holder
SR One Capital Management…
Held Float
View
Held by Funds
Fund positions
152
View
Short & Settlement
Short Interest Falling
Shares short
5.5M
Days to cover
9.0d
Change
-383.1K sh
View
Short Volume
Short vol %
79%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
5
Value
$61
As of
Aug 3, 2026
View
Off-Exchange
Off-exchange %
34.2%
Week of
Aug 3, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-69.8M
EPS diluted
$-1.22
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 3, 2026
This year
13
View
Proposed Sales
Value
$891.6K
Shares
120.0K
Filed
Nov 18, 2025
View
Exempt Offerings
Offering
$125.0M
Filed
Feb 12, 2021
View
Earnings & Events
Earnings Calls
Last call
Jun 4, 2026
View

Performance

5D 20D 120D MTD YTD
DSGN -2.7% +1.7% +41.9% -3.1% +56.0%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -1.5% +3.4% +24.1% -2.7% +43.9%
Key facts CIK 1807120 CUSIP 25056L103 13F (30d) 80 filings 80 filers Visit website Investor relations